Molecular Partners To Present Initial Data From Ongoing Phase 1/2a Trial Of MP0533 For Patients With Relapsed/Refractory AML And AML/MDS At The 65th ASH Annual Meeting And Exposition
Author: Benzinga Newsdesk | November 02, 2023 03:00am
As of data cut-off (20 July 2023) of the abstract published today, five patients across three dosing regimens had been treated. The preliminary data reported indicate an acceptable safety profile, with no dose-limiting toxicity or Grade ≥3 adverse reactions. Grade 1/2 events considered related to MP0533 included infusion-related reactions and cytokine release syndromes.
Posted In: MOLN